Telemedicine Flexibilities Pertaining to Controlled Substances Extended Again!
October 24, 2023
A pandemic-era policy that allowed physicians to prescribe controlled substances based on a telehealth visit has been extended once again – this time to Dec. 31, 2024.
The policy was set to expire with the end of the public health emergency on May 11. Instead, the Drug Enforcement Agency (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) initiated a temporary rule that extended the current telemedicine flexibilities for prescribing controlled substances.
Now the DEA and the Department of Health and Human Services (HHS) have initiated a Second Temporary Rule to extend the expiration date to Dec. 31, 2024.
The main purpose of this extension is to give HHS and the DEA additional time to evaluate feedback regarding whether and how the temporary flexibilities could be made permanent. See the Background under “SUPPLEMENTARY INFORMATION” (scroll down) of the Federal Register for context.
If you have questions, please contact us by email
A pandemic-era policy that allowed physicians to prescribe controlled substances based on a telehealth visit has been extended once again – this time to Dec. 31, 2024.
The policy was set to expire with the end of the public health emergency on May 11. Instead, the Drug Enforcement Agency (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) initiated a temporary rule that extended the current telemedicine flexibilities for prescribing controlled substances.
Now the DEA and the Department of Health and Human Services (HHS) have initiated a Second Temporary Rule to extend the expiration date to Dec. 31, 2024.
The main purpose of this extension is to give HHS and the DEA additional time to evaluate feedback regarding whether and how the temporary flexibilities could be made permanent. See the Background under “SUPPLEMENTARY INFORMATION” (scroll down) of the Federal Register for context.
If you have questions, please contact us by email